This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO-Asia, Singapore 22-24 November 2019

Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm+) advanced NSCLC: updated data from the GioTag real-world study 

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Angela Märten, Tanja Cufer

esmo_asia_giotag_poster_1200.286.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

This video abstract summarizes updated results, including overall survival data, from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations.

6 mins 42 secs

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

Rate this

Optimizing outcomes and treatment sequences in EGFR mutation-positive NSCLC: recent updates

Nicolas Girard Future Oncology 2019 15(25), 2983-2997 doi: 10.2217/fon-2019-0400

FOR HEALTHCARE PROFESSIONALS ONLY

image